Our data showed that 4bt, one of the KIF11 inhibitors evaluated on this work, was able to hold tumor growth when used as monotherapy, however it presented more pronounced antitumor effects when used in combination with other drugs, as already pointed for other KIF11 inhibitors [43, 44]. The gene discussed is KIF11; the disease is neoplasm.